Resources:
In the first webinar – held on 22 April 2021 – we discussed the implications of the EMA’s Guidelines across the HTA/Payer world on study designs, methodologies and for the future applicability of RWE requirements. Consideration was also given to whether cross-country and cross-stakeholder collaboration should aim to achieve convergence of guidelines, metrics and methodologies for the acceptance of RWE.
CEO of RIZIV-INAMI
Senior pharmacoepidemiologist and head of data analytics, European Medicines Agency
Head of HTA Strategy and External Engagement, National Centre for Pharmacoeconomics (NCPE) – Ireland
Acting Head of Drug Department, Federal Joint Committee (G-BA) – Germany
Data Analyst Coordinator, Monitoring Registries Office, Italian Medicines Agency (AIFA) – Italy
Pharmacoeconomist, Finnish Medicines Agency (FIMEA) – Finland
Head of Health Technology Assessment, Pricing and Reimbursement Division (DATS) and the Information and Strategic Planning Division (INFARMED) – Portugal
CEO of RIZIV-INAMI
In the spirit of a ‘Learning Network’, RWE4Decisions is hosting a series of three webinars to exchange experiences on existing guidance and initiatives seeking to ensure robustness of Real-World Evidence (RWE). The objective is to enable an open exchange and foster mutual learnings to identify current barriers, enablers and possible collaborative opportunities to enhance efficiencies and provide useful guidance to create a harmonised approach to RWE generation that strengthens trust in the use of real-world evidence for decision-making.
Public Webinar: From Policy to Practice: EHDS Implementation to Support Better Real-World Evidence for HTA/Payers
RWE4Decisions Symposium: Developing Real-World Evidence to Deliver Innovation in HTA
Public Webinar: HTA/Payer Collaboration in the Nordics: The Role of Real-World Evidence
